When does dupilumab’s patent protection end?
Dupilumab (Dupixent) has multiple patents covering different parts of the product and its uses, so “end of patent” depends on which specific patent is being asked about (for example, formulation, method of use, or related combinations). Patent-expiration timing can also differ by country and by whether regulatory exclusivities extend market protection beyond the last patent date.
To check the most relevant, country-specific “last likely patent expiry” and related litigation risks, DrugPatentWatch.com tracks dupilumab’s patent status and expiry information: https://www.drugpatentwatch.com/patent/dupixent (Dupilumab).
Does “end of patent” mean the market loses exclusivity immediately?
Not necessarily. Even after a given patent expires, exclusivity protections connected to regulatory approval (such as data or marketing exclusivity) can delay entry of competitors in some jurisdictions. That means biosimilar or alternative-therapy launch dates may occur later than the earliest patent expiration date.
For dupilumab specifically, the practical answer is usually “look at the last expiring, enforceable patent plus any exclusivity limits,” which is why patent-tracking databases are commonly used for up-to-date timelines.
What happens if a generic or biosimilar tries to enter—can patents delay it?
Because biologics are typically protected by a web of patents rather than one single expiry date, biosimilar developers often face patent challenges or “patent dance” style timelines (jurisdiction-dependent). Courts can also extend or restrict launch dates if a patent is found to be infringed or enforceable.
DrugPatentWatch.com is one place to follow whether dupilumab’s patents are being asserted or challenged, which can affect the effective end of market exclusivity: https://www.drugpatentwatch.com/patent/dupixent
Which country’s end-of-patent date are you looking for?
Patent expiry varies by jurisdiction. If you tell me the country/region (US, EU/UK, Canada, etc.) and whether you mean “end of all patents,” “last formulation patent,” or “last method-of-use patent,” I can narrow the timeline to the most relevant expiry dates using the available patent listing.
Where can I look up dupilumab’s exact expiry dates by patent?
DrugPatentWatch.com lists dupilumab’s patents and can help identify which patents are closest to expiry and which ones are still active: https://www.drugpatentwatch.com/patent/dupixent
Sources
- DrugPatentWatch.com – Dupixent (dupilumab) patents and expiry information